Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aim: To investigate the efficacy and safety of beinaglutide as an adjunct to lifestyle intervention among non‐diabetic Chinese individuals with overweight or obesity. Methods: This multicentre, randomized, double‐blind, placebo‐controlled trial (ChiCTR1900023428) included 427 Chinese adults with a body mass index of 28 kg/m 2 or higher (obesity) or 24‐27.9 kg/m 2 (overweight) with weight‐related complications. Patients were randomized in a 2:1 ratio to receive 0.2 mg of beinaglutide (subcutaneous) thrice daily or placebo for 16 weeks. Co‐primary endpoints were body weight change and the proportion of patients with a weight reduction of 5% or more. Results: Mean body weight change from baseline to week 16 was −6.0% and −2.4% in the beinaglutide ( n = 282) and placebo ( n = 138) groups, respectively; the mixed model repeated measures difference was −3.6% (95% confidence interval: −4.6% to −2.6%; P < .0001). At week 16, more beinaglutide‐treated patients achieved a weight reduction of 5% or more (58.2% vs. 25.4% [placebo], odds ratio: 4.4; P < .0001) and of 10% or more (21.3% vs. 5.1% [placebo], odds ratio: 5.5; P < .0001). Beinaglutide also resulted in greater waist circumference reduction (difference: −1.81 cm; P < .01). The weight regain rate 12 weeks after beinaglutide treatment was 0.78%. Nausea (transient and mild‐to‐moderate) was the most common adverse event in the beinaglutide group (49.3% vs. 7.1% [placebo]). More patients receiving beinaglutide discontinued treatment because of adverse events (5.9% vs. 0.7% [placebo]). Pancreatitis or an increased resting heart rate was not observed in the beinaglutide group. Conclusion: Beinaglutide combined with lifestyle intervention resulted in significant and clinically meaningful weight reduction with good tolerance in non‐diabetic Chinese individuals with overweight or obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“FAS, full analysis set; OD, odds ratio. which recruited female proportions that ranged from 73.1% to 78.1% 8,9 ; therefore, future investigations on sex differences in response to beinaglutide treatment are warranted.”
BackgroundInfluentialA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Progress and challenges in anti-obesity pharmacotherapy
Bessesen, D. H., & Van Gaal, L. F. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30236-x · Cited by 347
Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140
Food and Drug Administration's Obesity Drug Guidance Document: A Short History
Colman, E. (2012) · Circulation · doi:10.1161/circulationaha.111.028381 · Cited by 101
Zhang, F., Chen, Z., Wu, D., Tian, L., Chen, Q., Ye, Y., Chen, W., Wu, X., Wu, P., Yuan, W., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103382 · Cited by 54
Zhang, Y. L., Zhou, C., Li, X. F., Yang, M. N., Tao, L., Zheng, X. Y., & Jia, Y. S. (2019) · Obesity Science & Practice · doi:10.1002/osp4.342 · Cited by 49
Gao, L., Huang, H., Zhang, L., Zhang, N., Fu, Y., Zhu, D., Bi, Y., & Feng, W. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1608-0345 · Cited by 24 · cited 2×
“12 These findings, which are consistent with those from previous studies on beinaglutide, 16,17 combined with lifestyle intervention in non-diabetic patients with overweight or obesity.”
BackgroundResultInfluential
Research works printed but not linked: 14
- 10.1155/2022/5476454 · DOI
- 10.1056/NEJMoa1614362 · DOI · Paper page
- 10.1016/S2213-8587(21)00045-0 · DOI · Paper page
- 10.1038/s41467-018-05383-2 · DOI · Paper page
- 10.1016/j.isci.2022.104809 · DOI
- 10.1016/j.lfs.2020.118966 · DOI · Paper page
- 10.1002/dmrr.3158 · DOI · Paper page
- Wang G, 2021, Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity arch, Endocrinol Metab, 65, 421
- Zhou BF, 2002, Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults–study on optimal cut‐off points of body mass index and waist circumference in Chinese adults, Biomed Environ Sci, 15, 83
- 10.2337/dc20-S008 · DOI · Paper page
- 10.1161/JAHA.113.000668 · DOI · Paper page
- 10.1016/j.atherosclerosis.2011.06.033 · DOI
- 10.1186/s12916-022-02273-9 · doi:10.1186/s12916-022-02273-9
- 10.1038/nrcardio.2016.84 · DOI
Cited by
Moiz, A., Filion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01590 · Cited by 149
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
Ji, L., Jiang, H., Bi, Y., Li, H., Tian, J., Liu, D., Zhao, Y., Qiu, W., Huang, C., Chen, L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2411528 · Cited by 125
Self-citationTzang, C.-C., Wu, P.-H., Luo, C.-A., Chen, Z.-T., Lee, Y.-T., Huang, E. S., Kang, Y.-F., Lin, W.-C., Tzang, B.-S., & Hsu, T.-C. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103680 · Cited by 73
Xie, Z., Zheng, G., Liang, Z., Li, M., Deng, W., & Cao, W. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156038 · Cited by 54
Budini, B., Luo, S., Tam, M., Stead, I., Lee, A., Akrami, A., Vidal-Puig, A., & Park, A. (2026) · eClinicalMedicine · doi:10.1016/j.eclinm.2026.103796 · Cited by 52
Metadata
- Authors
- Chen, K., Chen, L., Shan, Z., Wang, G., Qu, S., Qin, G., Yu, X., Xin, W., Hsieh, T., & Mu, Y.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2023-11-09
- Volume
- 26
- Issue
- 2
- Pages
- 690-698
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4388550897
- Cited by
- 35
- References
- 9
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study. https://app.cochat.ai/papers/10.1111/dom.15360
- The paper
- Chen, K., Chen, L., Shan, Z., Wang, G., Qu, S., Qin, G., Yu, X., Xin, W., Hsieh, T., & Mu, Y. (2024). Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15360
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.